Medical Imaging Entrepreneur Joins Median eyonis Inc. as President

Median Technologies has named Oran Muduroglu as president of Median eyonis Inc., the company’s U.S. subsidiary. He will continue to be executive chairman of Median’s Board of Directors while assuming operational leadership of U.S. commercialization.

Muduroglu will lead the U.S. launch and scale-up of eyonis LCS, an artificial intelligence (AI)-powered Software as a Medical Device (SaMD) for lung cancer screening, following U.S. Food and Drug Administration (FDA) 510(k) clearance earlier this year.

“With FDA clearance secured, a defined Medicare reimbursement pathway in place, and a uniquely differentiated solution developed through the exceptional scientific and engineering leadership of our colleagues in France, we are entering this launch with strong momentum,” Muduroglu said. “Our focus now is disciplined execution—aligning payers, distribution partners, and providers around a solution that directly addresses one of the key drivers of non-adherence in lung cancer screening. By reducing uncertainty and false positives, we seek to enable earlier diagnosis, improve physician productivity, and strengthen both the clinical and economic performance of screening programs. We believe eyonis LCS can materially improve patient confidence and engagement and help health systems focus on patients who truly require intervention. That combination of clinical performance and economic value will drive adoption at scale.”

Muduroglu has more than three decades of experience building, engineering, and scaling enterprise imaging and workflow platforms, consistently translating technical innovation into broad U.S. adoption. He led the sale of Cemax to 3M/Imation in 1995, helping accelerate the transition to modern Picture Archiving and Communication Systems (PACS). Muduroglu later co-founded Stentor, acquired by Philips in 2005, which became one of the first enterprise platforms enabling fully digital imaging workflows and an early SaaS model in medical imaging, reaching the number two U.S. market position within three years.

As CEO of Medicalis, acquired by Siemens Healthineers in 2017, Muduroglu led the commercialization of a clinical decision support and workflow platform adopted by approximately nine of the top 15 U.S. health systems. In 2018, Alphabet’s Verily recruited him to develop a value-based care platform supporting physician groups in managing Medicare Advantage risk.

Across these ventures, Muduroglu has led complex national deployments requiring deep electronic medical records (EMR) and PACS interoperability, rigorous product development, disciplined enterprise sales, and alignment with evolving reimbursement models—experience directly relevant to the U.S. launch of eyonis LCS.

“Oran is a highly respected leader with deep operational rigor and commercialization expertise,” Median Technologies Founder/CEO Fredrik Brag stated. “His experience scaling imaging platforms nationally makes him qualified to lead this next phase of growth.”

During development and validation of eyonis LCS, the eyonis team built strong awareness and credibility among radiologists, pulmonologists, and oncologists through presentations at major medical congresses and engagement with academic centers. Building on this foundation, the company is actively engaged in discussions to establish key clinical partnerships designed to create broad access across U.S. lung cancer screening programs.

With eyonis LCS’ FDA clearance, Median has activated a phased U.S. launch strategy created through detailed customer and payor mapping, which prioritized regions with strong lung cancer screening volumes and favorable reimbursement dynamics.

To support the launch strategy, Median eyonis Inc. is expanding its U.S.-based commercial and clinical support teams and will deploy a coordinated strategy designed to combine direct enterprise sales, strategic distribution partnerships, and seamless workflow integration.

Median also has executed a non-exclusive distribution agreement with Tempus AI, a U.S technology company advancing precision medicine through AI adoption. The non-exclusive distribution agreement leverages Tempus’ established position in oncology and AI-based precision medicine, and its network of healthcare providers, oncologists, and diagnostic centers. Tempus’ integration of eyonis LCS into its Pixel platform reinforces the clinical utility of the technology and facilitates adoption through an established enterprise workflow, according to the companies. This collaboration is designed to enhance eyonis LCS’ commercial availability in the United States.

Median plans to broaden commercial adoption of eyonis LCS by targeting additional non-exclusive distribution agreements with top-tier imaging and cloud technology partners as well as diagnostics partners.

The launch leverages the existing Centers for Medicare and Medicaid Services’ (CMS) reimbursement framework. eyonis LCS is reimbursable under the New Tech APC pathway, as an initial bridge toward broader and more durable coverage. For 2026, the Medicare Outpatient Prospective Payment System (OPPS) will pay approximately $601–$700 per exam, providing a predictable payment pathway for providers. Approximately 14.5 million Americans meet U.S. Preventive Services Task Force (USPSTF) eligibility criteria for lung cancer screening, supporting substantial adoption potential.

The Company expects its first U.S. sites to be operational in the next quarter.

Pioneering software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis, an AI/ML tech-based suite of software as a medical device (SaMD). With a presence in the United States and China, the French-based company trades on the Euronext Growth market.